Press Releases

 

Financial

  Date Title and Summary View
Mar 16, 2017
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GE...
Mar 9, 2017
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
Feb 15, 2017
LAWRENCEVILLE, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of a public offering with expected total gross proceeds of approximately $5.0 million. The offering was priced at $0.23 per share of common stock (or common stock equivalent), with each share of common stock (o...
Dec 20, 2016
LAWRENCEVILLE, N.J., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $1.8 million of shares of common stock in a registered direct offering. The Company agreed to...
Nov 3, 2016
LAWRENCEVILLE, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and nine-month period ended September 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated lipo...
Sep 7, 2016
Optima, a Global Phase III Study in Newly Diagnosed Primary Liver Cancer Patients Ovation, a Study of Gene-mediated Immuno-therapy in 1st line Ovarian Cancer LAWRENCEVILLE, N.J., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Mr. Michael H. Tardugno, Chairman and CEO and Mr. Jeffrey W. Church, Sr. ...
Aug 15, 2016
Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses Company to Hold Conference Call on Monday, August 15, 2016 at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today...
Aug 8, 2016
LAWRENCEVILLE, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and six-month period ended June 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal ...
Jun 13, 2016
LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase an aggregate of approximately $6 million of shares of common stock, or pre-funded warrants in lieu thereof, i...
May 16, 2016
LAWRENCEVILLE, N.J., May 16, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Share This